Published in Clin Cancer Res on October 15, 2007
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A (2010) 2.67
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther (2011) 1.98
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol (2015) 1.73
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer (2011) 1.73
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat (2010) 1.60
PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res (2010) 1.49
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res (2012) 1.47
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res (2009) 1.45
Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res (2009) 1.41
Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol (2010) 1.27
Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One (2014) 1.18
Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. PLoS One (2014) 1.17
Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res (2010) 1.10
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One (2014) 1.07
Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat (2012) 1.05
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch (2008) 1.05
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol (2012) 1.04
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res (2008) 1.02
PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer (2013) 0.99
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res (2014) 0.97
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World J Gastroenterol (2012) 0.97
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res (2010) 0.97
Phosphatidylinositol 3-kinase in breast cancer: where from here? Clin Cancer Res (2007) 0.91
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo) (2012) 0.91
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast Cancer Res (2014) 0.88
PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer (Dove Med Press) (2015) 0.88
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer (2012) 0.88
Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clin Adv Hematol Oncol (2013) 0.87
Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. Oncogenesis (2013) 0.87
Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Sci Rep (2014) 0.86
The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets (2008) 0.86
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. BMC Clin Pathol (2015) 0.84
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol (2010) 0.83
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch (2012) 0.83
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients. Cancer Biol Ther (2013) 0.83
PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis. Onco Targets Ther (2014) 0.79
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. PLoS One (2015) 0.79
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. Virchows Arch (2014) 0.79
Dual FGF-2 and intergrin alpha5beta1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy. Cancer Microenviron (2009) 0.79
Retracted Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Br J Cancer (2014) 0.79
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Virchows Arch (2016) 0.78
Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybridization impact on prognosis in breast cancer. Cancer Sci (2015) 0.76
Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget (2016) 0.75
Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations. Int J Clin Exp Pathol (2014) 0.75
PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma. World J Gastroenterol (2017) 0.75
Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors. Mol Oncol (2017) 0.75
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol (2010) 7.29
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 5.07
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol (2006) 2.77
Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol (2006) 2.59
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol (2011) 2.44
Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst (2008) 2.36
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol (2008) 2.24
Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst (2006) 2.16
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
Assessing EGFR mutations. N Engl J Med (2006) 1.83
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat (2008) 1.64
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
User attitudes in analyzing digital slides in a quality control test bed: a preliminary study. Comput Methods Programs Biomed (2006) 1.57
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer (2006) 1.55
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med (2007) 1.52
High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer (2003) 1.49
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest (2007) 1.41
M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer (2006) 1.38
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Survivin gene expression in early-stage non-small cell lung cancer. J Pathol (2003) 1.35
Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: interval breast cancers at 1 year follow-up. Eur J Cancer (2011) 1.33
microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol (2013) 1.31
Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol (2012) 1.29
Pain and quality of life after surgery for breast cancer. Breast Cancer Res Treat (2003) 1.29
Breast screening with ultrasound in women with mammography-negative dense breasts: evidence on incremental cancer detection and false positives, and associated cost. Eur J Cancer (2008) 1.28
Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch (2012) 1.24
Digital storage of glass slides for quality assurance in histopathology and cytopathology. J Telemed Telecare (2002) 1.23
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J (2009) 1.23
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer (2009) 1.17
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res (2002) 1.16
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia (2009) 1.15
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res (2012) 1.15
HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer (2007) 1.15
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. J Thorac Oncol (2015) 1.14
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol (2006) 1.11
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol (2005) 1.09
Experience in designing and evaluating a Teleconsultation System supporting shared care of oncological patients. AMIA Annu Symp Proc (2003) 1.07
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. Clin Cancer Res (2005) 1.03
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res (2005) 1.03
Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica (2010) 1.00
Pulmonary glomus tumor. Int J Surg Pathol (2008) 1.00
HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res (2003) 1.00
A unique microRNA signature associated with plaque instability in humans. Stroke (2011) 1.00
Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology (2012) 0.98
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. Hum Mutat (2009) 0.97
Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS One (2012) 0.96